Tous Actualités
Suivre
Abonner Isotechnika Inc.

Isotechnika Inc.

Isotechnika Announces Ninety Per Cent Participation in Phase III Psoriasis Extension Trial

Edmonton, Canada (ots/PRNewswire)

Isotechnika Inc. (TSX: ISA)
announced today the participation level in  its Canadian Phase III
psoriasis extension trial for its lead  immunosuppressive drug,
ISA247.
Patients completing the 24 week Canadian Phase III SPIRIT trial
were given the opportunity to continue therapy for an additional 36
weeks or to discontinue therapy. Of the patients who completed the 24
week trial 90% chose to continue treatment. The patients who enrolled
in the open label extension trial are receiving administration of
oral ISA247 capsules at 0.3 mg/kg twice daily, which was the mid-dose
used in the SPIRIT trial. The goals of the extension trial are to
provide continued therapeutic benefit to psoriasis patients and to
gather longer term safety and efficacy data. This data should
facilitate the advancement of ISA247 through the clinical trial
process.
"As a clinical investigator with 20 years experience, the 90%
enrollment in the current Isotechnika Phase III extension trial for
psoriasis speaks volumes. It indicates patients are extremely
satisfied and pleased with not only the efficacy, but the safety of
this drug. Typically, extension studies do not normally attain such
high enrollment figures," commented Dr. Charles Lynde, a principal
investigator involved in the Phase III psoriasis trial.
"The overwhelming participation in this extension trial attests to
the high degree of acceptance of ISA247 by both the patients and the
physicians," stated Dr. Randall Yatscoff, Isotechnika's President &
COO. "We are confident that the unblinded 12 week data from the
SPIRIT trial will continue to demonstrate a promising safety and
efficacy profile for ISA247. The 12 week unblinded results are
expected to be announced in the next few weeks."
Edmonton-based Isotechnika Inc. is an international
biopharmaceutical company focused on the discovery and development of
novel immunosuppressive therapeutics that are safer than currently
available treatments. To find out more about Isotechnika Inc. (TSX:
ISA), please visit our Web site at www.isotechnika.com.
Forward-Looking Statements
This press release may contain forward-looking statements.
Forward- looking statements, including the Company's belief as to the
potential of its products, the Company's expectations regarding the
issuance of additional patents and the Company's ability to protect
its intellectual property, involve known and unknown risks and
uncertainties, which could cause the Company's actual results to
differ materially from those in the forward- looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue research and development projects, the
ability to economically manufacture its products, the potential of
its products, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialise its
products, the ability of the Company to defend its patents from
infringement by third parties, and the risk that the Company's
patents may be subsequently shown to be invalid or infringe the
patents of others. Investors should consult the Company's quarterly
and annual filings with the Canadian commissions for additional
information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements.
To request a free copy of this organisation's annual report,
please go to http://www.newswire.ca and click on reports@cnw.

Contact:

Dr. Randall Yatscoff, President & COO, Isotechnika Inc., Tel:
+1-(780)-487-1600 Ext. 246, Fax: +1-(780)-484-4105, Email:
ryatscoff@isotechnika.com; Stephanie Gillis-Paulgaard, Senior
Manager, Corporate Communications, Isotechnika Inc., Tel:
+1-(780)-487-1600 Ext. 243,
Fax: +1-(780)-484-4105, E-mail: sgillis-paulgaard@isotechnika.com;
Archived
images on this organization are searchable through CNW Photo Archive
website
at http://photos.newswire.ca. Images are free to accredited members
of the
media

Plus de actualités: Isotechnika Inc.
Plus de actualités: Isotechnika Inc.
  • 03.08.2005 – 13:03

    Isotechnika Announces Interim Blinded Phase III Psoriasis Results

    Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX: ISA) announced today that the Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247, continues to demonstrate a promising safety and efficacy profile. The Canadian Phase III Psoriasis (SPIRIT) trial commenced on December 2, 2004 and includes a total of 453 patients with ...

  • 12.05.2005 – 13:31

    Isotechnika Granted Permission From FDA for Phase IIb Kidney Transplant Trial

    Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has received permission from the Food and Drug Administration of the United States to proceed with a Phase IIb kidney transplant trial for its lead immunosuppressive drug, ISA247. The planned randomized, open-label trial will include approximately 332 de novo (newly ...

  • 09.05.2005 – 15:02

    Isotechnika Announces Web Cast Details for Annual General Meeting

    Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced today that the Company will web cast its Annual General Meeting in Toronto on Tuesday, May 10, 2005 at 10:00 a.m. EDT. The web cast will include corporate and scientific updates. The web cast will be chaired by Dr. Robert Foster, Chairman and CEO; with Dr. Randall Yatscoff, President and COO presenting the scientific update. Interested parties can ...